{"id":"abarelix","rwe":[{"pmid":"39861098","year":"2024","title":"GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"34187259","year":"2021","title":"Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.","finding":"","journal":"Expert opinion on pharmacotherapy","studyType":"Clinical Study"},{"pmid":"32396496","year":"2020","title":"Erythropoietin-producing hepatocellular receptor A7 restrains estrogen negative feedback of luteinizing hormone via ephrin A5 in the hypothalamus of female rats.","finding":"","journal":"American journal of physiology. Endocrinology and metabolism","studyType":"Clinical Study"},{"pmid":"28870102","year":"2017","title":"Therapeutic outcomes of the LHRH antagonists.","finding":"","journal":"Expert review of pharmacoeconomics & outcomes research","studyType":"Clinical Study"},{"pmid":"24775720","year":"2014","title":"Utility of LHRH antagonists for advanced prostate cancer.","finding":"","journal":"The Canadian journal of urology","studyType":"Clinical Study"}],"tags":[{"label":"abarelix","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"L02BX01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Ischemic priapism","category":"indication"},{"label":"Speciality European","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Hormone Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"commonSideEffects":[],"contraindications":["Breastfeeding (mother)","Liver function tests abnormal","Obesity","Pregnancy, function","Prolonged QT interval"]},"trials":[],"aliases":[],"company":"Speciality European","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ABARELIX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:07:55.673513+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Abarelix","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:08:03.412390+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:08:01.989153+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ABARELIX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:08:02.337270+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:08:03.412334+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1252/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:08:03.064400+00:00"}},"allNames":"plenaxis","offLabel":[],"synonyms":["abarelix","plenaxis","PPI-149","R3827"],"timeline":[{"date":"2003-11-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Speciality European)"}],"brandName":"Plenaxis","ecosystem":[{"indication":"Ischemic priapism","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"}],"modality":"Small Molecule","drugClass":"abarelix","explanation":"","oneSentence":"","technicalDetail":"Abarelix is a competitive antagonist of the gonadotropin-releasing hormone receptor, which inhibits the release of gonadotropin-releasing hormone and subsequently reduces the secretion of luteinizing hormone and follicle-stimulating hormone."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Abarelix","title":"Abarelix","extract":"Abarelix, sold under the brand name Plenaxis, is an injectable gonadotropin-releasing hormone antagonist which is marketed in Germany and the Netherlands. It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-11-25, SPECIALITY EUROPEAN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/35","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ABARELIX","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ABARELIX","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Abarelix","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T07:26:27.897190","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:04.680076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"degarelix","drugSlug":"degarelix","fdaApproval":"2008-12-24","patentExpiry":"Feb 20, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"abiraterone acetate","drugSlug":"abiraterone-acetate","fdaApproval":"2011-04-28","patentExpiry":"May 20, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"relugolix","drugSlug":"relugolix","fdaApproval":"2020-12-18","patentExpiry":"Sep 29, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"abarelix","indications":{"approved":[{"name":"Ischemic priapism","source":"DrugCentral","snomedId":441575009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"degarelix","brandName":"degarelix","genericName":"degarelix","approvalYear":"2008","relationship":"same-class"},{"drugId":"abiraterone-acetate","brandName":"abiraterone acetate","genericName":"abiraterone acetate","approvalYear":"2011","relationship":"same-class"},{"drugId":"relugolix","brandName":"relugolix","genericName":"relugolix","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"enrollment":31,"completionDate":"2026-08-27"},{"nctId":"NCT06157528","phase":"NA","title":"Diagnosis of Pelvic Endometriosis in MRI","status":"NOT_YET_RECRUITING","sponsor":"Zhenshen Ma","startDate":"2023-12-20","conditions":["Endometriosis"],"enrollment":100,"completionDate":"2029-12"},{"nctId":"NCT00841113","phase":"PHASE3","title":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Speciality European Pharma Limited","startDate":"1999-01","conditions":["Prostate Cancer"],"enrollment":177,"completionDate":"2003-02"},{"nctId":"NCT00103623","phase":"PHASE4","title":"The Plenaxis® Experience Study","status":"SUSPENDED","sponsor":"PRAECIS Pharmaceuticals Inc.","startDate":"2004-06","conditions":["Prostate Cancer"],"enrollment":2000,"completionDate":"2008-12"},{"nctId":"NCT00100243","phase":"PHASE2","title":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","status":"COMPLETED","sponsor":"PRAECIS Pharmaceuticals Inc.","startDate":"2004-05","conditions":["Prostate Cancer"],"enrollment":22,"completionDate":"2005-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148825","MMSL":"17679","NDDF":"008459","UNII":"W486SJ5824","VUID":"4021410","CHEBI":"CHEBI:337298","VANDF":"4021410","INN_ID":"7689","RXNORM":"301739","UMLSCUI":"C0965390","chemblId":"CHEMBL1252","ChEMBL_ID":"CHEMBL1252","KEGG_DRUG":"D02738","DRUGBANK_ID":"DB00106","PUBCHEM_CID":"16131215","SNOMEDCT_US":"407128008","IUPHAR_LIGAND_ID":"1188","MESH_SUPPLEMENTAL_RECORD_UI":"C423508"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Speciality European","relationship":"Original Developer"}],"publicationCount":55,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"L02BX01","allCodes":["L02BX01"]},"biosimilarFilings":[],"originalDeveloper":"Speciality European","recentPublications":[{"date":"2024 Dec 31","pmid":"39861098","title":"GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2021 Dec","pmid":"34187259","title":"Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.","journal":"Expert opinion on pharmacotherapy"},{"date":"2020 Jul 1","pmid":"32396496","title":"Erythropoietin-producing hepatocellular receptor A7 restrains estrogen negative feedback of luteinizing hormone via ephrin A5 in the hypothalamus of female rats.","journal":"American journal of physiology. Endocrinology and metabolism"},{"date":"2017 Oct","pmid":"28870102","title":"Therapeutic outcomes of the LHRH antagonists.","journal":"Expert review of pharmacoeconomics & outcomes research"},{"date":"2014 Apr","pmid":"24775720","title":"Utility of LHRH antagonists for advanced prostate cancer.","journal":"The Canadian journal of urology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Speciality European","companyId":"speciality-european","modality":"Recombinant protein","firstApprovalDate":"2003","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:08:04.680076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}